Drugs / CN54gp140
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02589795 | Aug 2016 → Dec 2017 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
| Phase 1 | NCT00637962 | Sep 2007 → Oct 2008 | AIDS | St George's, University of London | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04066881 | Dec 2020 → Dec 2024 | HIV infectious disease | MRC/UVRI and LSHTM Uganda Research Unit | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04844775 Background | Aug 2022 → Sep 2024 | — | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 1 | NCT01966900 Comparator | Oct 2013 → Nov 2015 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CN54 gp140 | “We conducted a phase 1 double-blind randomised controlled trial (RCT) of a HIV-1 envelope protein (CN54 gp140) candidate vaccine delivered vaginally to assess immunogenicity and safety.” PMID 21984924 ↗ Sep 2011 |
| Modality | Vaccine | “CN54gp140 vaccine” NCT00637962 ↗ |
| Route | Intramuscular | “Each dose will be an intramuscular injection of 100 micrograms of CN54gp140 mixed with 5 micrograms of GLA-AF” NCT01966900 ↗ |